歌礼制药-B(01672)将在第61届欧洲糖尿病研究协会(EASD)年会上报告ASC30 口服小分子GLP-1R激动剂28天多剂量递增研究结果

Core Viewpoint - The company is set to present clinical data for ASC30, an oral small molecule GLP-1 receptor agonist, at the 61st European Association for the Study of Diabetes (EASD) annual meeting in Vienna, Austria, highlighting its potential as a differentiated treatment for obesity [1] Company Summary - The CEO of the company, Dr. Wu Jinzi, expressed optimism about the clinical efficacy and safety data for ASC30, suggesting it could become a unique solution for obesity treatment [1] - ASC30 is a new chemical entity (NCE) with both oral and subcutaneous administration capabilities, supported by patent protection in the U.S. and globally until 2044, excluding any patent extensions [1]